FILTER
FILTERED INTERVIEW RESULTS
Ricardo Cuetos
VP AMERICAS STANDARD PRODUCTS, INEOS STYROLUTION
INEOS Styrolution explains the current market dynamics of the America’s and how it’s various units are coping.
Stefan Lepecki
CEO, BRASKEM IDESA
Braskem Idesa speaks of the impact of the COVID-19 pandemic on the polyethylene industry and how the company and Mexico are faring.
Miguel Benedetto
DIRECTOR GENERAL, ANIQ
ANIQ describe the impact of the Coronavirus on Mexico’s chemical industry and outlines the challenges of the year ahead.
Rodrigo Gutierrez
CEO, GTM HOLDINGS
GTM Holdings explains its outlook for the Latin American industrial and specialty chemicals market for the next year.
Martin Sack
REGIONAL HEAD AMERICAS, LESCHACO
Leschaco is a freight forwarder expanding its’ services and network across the Americas.
Edison Terra
VICE PRESIDENT OF OLEFINS AND POLYOLEFINS UNIT FOR SOUTH AMERICA, BRASKEM
Braskem is the largest petrochemical company in the Americas, the largest producer of polypropylene in the US, and a global leader in biopolymers production.
Jorge Buckup
PRESIDENT LATIN AMERICA, UNIVAR SOLUTIONS
Univar Solutions consolidates in the wider region through the Nexeo acquisition.
Martin Toscano
MANAGING DIRECTOR, EVONIK INDUSTRIES (MEXICO)
Evonik enjoys rapid growth in Mexico across all sectors, both in market share for existing products and as a result of acquisitions and diversification.
Eugenio Manzano
EXECUTIVE DIRECTOR, POCHTECA
Pochteca talks about its commitment to promoting equality in the workplace and supporting the communities in which the company operates.
Guillermo Laborato
PRESIDENT, LATIN AMERICA SOUTH, BRENNTAG
Despite a challenging economic environment, Brenntag’s Latin American operations continue to experience growth.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
